Table 1.
Summary of included studies for systematic review and meta-analysis
| First author | Published year | Paper type | Country | Study centre | Patients (n) | Patients with LC (%) | DAA regimen |
| Abbas26 | 2017 | Abstract | Pakistan | Single-centre | 241 | 64 | SOF+RBV 24 weeks; SOF+RBV+Peg-IFN 12 weeks |
| Akhter27 | 2016 | Full paper | Pakistan | Single-centre | 55 | NA | SOF+RBV 24 weeks; SOF+RBV+Peg-IFN 12 weeks |
| Capileno12 | 2017 | Full paper | Pakistan | Single-centre | 153 | 61 | SOF+RBV 24 weeks |
| Farooqi28 | 2016 | Abstract | Pakistan | NA | 47 | NA | SOF+RBV±Peg-IFN 12/24 weeks |
| Goel29 | 2017 | Full paper | India | Single-centre | 160 | 51 | SOF+RBV 24 weeks; SOF+RBV+Peg-IFN 12 weeks; DCV+SOF±RBV 12/24 weeks |
| Hlaing30 | 2017 | Full paper | Myanmar | Multicentre | 133 | 55 | SOF+RBV 24 weeks; SOF+RBV+Peg-IFN 12 weeks; DCV+SOF+RBV 12/24 weeks; LDV+SOF 12 weeks |
| Mehta31 | 2016 | Full paper | India | Single-centre | 67 | 64 | SOF+RBV±Peg-IFN 12/24 weeks |
| Merat32 | 2017 | Full paper | Iran | Single-centre | 44 | 100 | DCV+SOF+RBV 12 weeks |
| Sarwar33 | 2017 | Full paper | Pakistan | Single-centre | 198 | 52 | SOF+RBV±Peg-IFN 12/24 weeks |
| Satsangi34 | 2017 | Full paper | India | Single-centre | 105 | 33 | SOF+RBV 24 weeks; SOF+RBV+Peg-IFN 12 weeks |
| Shah35 | 2016 | Abstract | India | Multicentre | 59 | 24 | SOF+RBV 24 weeks; SOF+RBV+Peg-IFN 12 weeks |
| Sidhu36 | 2017 | Full paper | India | Multicentre | 931 | 21 | SOF+RBV 24 weeks; SOF+RBV+Peg-IFN 12 weeks |
| Sood9 | 2017 | Full paper | India | Single-centre | 589 | 46 | SOF+RBV 24 weeks; SOF+RBV+Peg-IFN 12 weeks |
| Win37 | 2016 | Abstract | Myanmar | NA | 73 | NA | SOF+RBV+Peg-IFN 12 weeks |
| Yousaf38 | 2017 | Abstract | Pakistan | Single-centre | 1375 | 0 | SOF+RBV 24 weeks; SOF+RBV+Peg-IFN 12 weeks |
DAA, direct-acting antiviral; DCV, daclatasvir; LC, liver cirrhosis; LDV, ledipasvir; NA, not available; Peg-IFN, pegylated interferon; RBV, ribavirin; SOF, sofosbuvir.